LLY · News · 20260914N

Products and Technology - Lp(a) drugs

ELI LILLY & Co · 2026-09-14 · Importance 17 · Surprise 24

Novartis reported unfavorable results for pelacarsen, its investigational Lp(a)-lowering drug. Lilly is also developing an Lp(a)-lowering therapy, potentially altering the competitive landscape for cardiovascular-risk treatments. The development affects Lilly’s positioning in a multibillion-dollar Lp(a) drug market, although no specific Lilly trial or commercial milestone was reported.